A Cell-Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer-Specific Synthetic...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer remains a significant global health challenge despite advancements in precision oncology.
• Targeting oncogene addiction is a key strategy in cancer therapy.
• Understanding novel mechanisms of cancer cell death is crucial for developing new treatments.

Purpose of the Study:

• To investigate the anti-cancer effects of a cell-penetrable peptide, ACP52C.
• To elucidate the molecular mechanisms by which ACP52C induces apoptosis in cancer cells.
• To explore the potential of ACP52C and its derivatives in anticancer drug development.

Main Methods:

• Utilized a cell-penetrable peptide (ACP52C) in cancer cell models.
• Investigated the dissociation of transcription factor CP2c complexes.
• Analyzed the interaction of dissociated CP2c with YY1 and TDP2.
• Examined the role of the MDM2-p53 pathway and DNA damage responses.
• Assessed the impact of MDM2 p60 expression and CASP2 inhibition on ACP52C efficacy.
• Evaluated the pharmacokinetics and anti-cancer effects of ACP52C derivatives.

Main Results:

• ACP52C induces apoptosis in CP2c oncogene-addicted cancer cells via transcription-independent mechanisms.
• Dissociated CP2c interacts with and degrades YY1, activating apoptosis through the MDM2-p53 pathway.
• Degraded CP2c inhibits TDP2, leading to genome-wide DNA strand breaks and damage responses.
• These effects are independent of cancer driver mutations but can be hindered by high MDM2 p60 expression.
• CASP2 inhibition sensitizes ACP52C-resistant cancers.
• ACP52C derivatives demonstrate improved pharmacokinetics and reduced tumor burden, even in resistant cancers.

Conclusions:

• ACP52C effectively induces cancer-specific apoptosis through novel molecular pathways.
• The study provides a strong rationale for developing ACP52C as an anticancer therapeutic.
• Targeting CP2c complexes and downstream effectors represents a promising strategy for cancer treatment.